•   
  •   

World Johnson & Johnson supplies Germany 6.5 million vaccine doses less than planned

19:40  12 june  2021
19:40  12 june  2021 Source:   sueddeutsche.de

COVID-19 Vaccine Maps Reveal Political Divide, Public Health Service Disparities

  COVID-19 Vaccine Maps Reveal Political Divide, Public Health Service Disparities It is "very disappointing" but "not surprising" that many conservative states are lagging behind blue states in COVID-19 vaccinations, according to American Public Health Association Executive Director Georges Benjamin.The Associated Press noted the slower rollout of COVID-19 vaccines in red states in mid-April. As of May 30, data from the Centers for Disease Control and Prevention (CDC) showed the five states with the lowest numbers of vaccine doses administered per 100,000 people were Mississippi, Alabama, Louisiana, Wyoming and Arkansas—each of which former President Donald Trump won last November.

After a breakdown in a vaccine plant in the US, Germany must renounce a large part of the deliveries promised by the manufacturer Johnson & Johnson for the time being. The pharmaceutical company will deliver about 6.5 million vaccine doses less in the second quarter as planned, said a spokeswoman for the Federal Ministry of Health on Saturday at AFP request. "That's regrets, because every vaccination box counts. So we expect Johnson & Johnson that this amount will be replenished as soon as possible in July."

Nach einer Panne in einem Impfstoff-Werk in den USA muss Deutschland auf einen Großteil der vom Hersteller Johnson & Johnson zugesagten Lieferungen vorerst verzichten. Das Unternehmen werde etwa 6,5 Millionen Impfdosen weniger liefern als geplant, erklärte das Bundesgesundheitsministerium. © Justin Tallis After a breakdown in a vaccine plant in the US, Germany must give up a large part of the deliveries promised by the manufacturer Johnson & Johnson for the time being. The company will deliver about 6.5 million vaccines less than planned, explained the Federal Ministry of Health.

Originally, in the current quarter after the delivery forecast published at the beginning of June, 10.1 million doses of the J & J vaccine in Germany arrive by the Ministry of Health.

Calls to fast-track Pfizer for Victoria amid ‘phenomenal demand' for vaccine

  Calls to fast-track Pfizer for Victoria amid ‘phenomenal demand' for vaccine The Australian Medical Association is pushing for GPs to be supplied with more COVID-19 vaccines amid a growing Pfizer shortage fuelled by a jump in Victorians getting a jab.The Australian Medical Association is pushing for COVID-19 vaccines to be fast-tracked into general practices amid a growing Pfizer shortage in Victoria fuelled by an explosion in the number of people getting vaccinated.

A breakdown in a plant in Baltimore had led to significant delivery difficulties. Several batches in the scope of several million doses are unusable because of possible contamination, the drug authority FDA announced on Friday. The "New York Times" reported citing informed circles that 60 million vaccine doses were affected. Canada announced a delivery stop for 300,000 affected vaccines and an inspection of the factory.

The company Emergent Biosolutions, which produces Corona vaccine for J & J in a plant in Baltimore in the US state of Maryland, had set production in April at the order of the FDA after the ingredients of the preparation exchanged with those of the Vaccine of AstraZeneca had been. Currently, it is still checked whether 60 million doses of the AstraZeneca vaccine produced in Baltimore comply with quality requirements. For ten million doses of the Vaccine of Johnson & Johnson, the FDA gave the release.

The Vaccine of J & J, which was initially produced exclusively in the Netherlands, had received an emergency approval in the US at the end of February. In mid-March, the vaccine was then approved in the EU. In contrast to the other previously approved Corona vaccines, the vaccine of Johnson & Johnson requires only one vaccination syringe for comprehensive protection.

BFI / YB

Australia's first locally made COVID-19 mRNA vaccine candidate is set for clinical trials .
Australia's first locally designed and manufactured COVID-19 mRNA vaccine could be within sight, with the first candidate due to start Phase 1 clinical trials by around October or November.

usr: 0
This is interesting!